Jacek Jassem is an expert in Oncology at Gdańsk Medical University (Poland). As of August 2026, ScienceLeadR ranks Jacek Jassem in the top 1% of experts worldwide for Bronchial Neoplasms, Thoracic Neoplasms and Lung Neoplasms. Jacek Jassem has authored 808 publications, the most recent in 2026, and is an investigator in 50 clinical trials, 3 of them ongoing. SLR score: 2,760 (community average: 125). How the SLR is computed.

LeadR Profile

Jacek Jassem Gdańsk Medical University Poland
2 760 ScienceLeadR Reputation 2760
Network Map

Oncology

Subspecialties: Biochemistry - Internal Medicine - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1975 - 2026

Source: PubMed

University of Gdańsk

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 808

Citations

Citations: 95 158 1st author: 66 Last author: 255 Unique author: 38


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.
PMID 42189888 — triple negative breast neoplasms, safety, breast neoplasms, paclitaxel, neoplasms, breast, therapeutics
Clin Cancer Res20260
First-line durvalumab in combination with trastuzumab deruxtecan in women with locally advanced unresectable or metastatic, hormone-receptor-negative, HER2-low breast cancer: multicenter, open-label, phase 1b/2 BEGONIA platform trial.
PMID 42259988 — safety, breast neoplasms, neoplasms, hormones, breast, therapeutics, trastuzumab
Nat Cancer20260
Final outcomes of the SOFT and TEXT phase III trials in premenopausal hormone receptor-positive early breast cancer.
PMID 42229584 — breast neoplasms, neoplasms, drug therapy, hormones, breast, therapeutics, tamoxifen, chemotherapy
Ann Oncol Top journal20260
Advancing Systemic Treatment beyond First Line for Advanced Hepatocellular Carcinoma.
PMID 42171914 — carcinoma, hepatocellular, neoplasms, immune checkpoint inhibitors, therapeutics
Curr Oncol Rep20260
Mutational landscapes of brain metastases across various histological subtypes of lung cancer.
PMID 41747607 — cells, genes, lung, brain, neoplasms, carcinoma, non-small-cell lung, lung neoplasms, neoplasm metastasis
Lung Cancer20260

Clinical Studies 50

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 1 Study Chair: 1

By phase:

Phase 3 40
Phase 2 8
Phase 1/Phase 2 2

By status:

Completed 33
Active not recruiting 10
Terminated 6
Suspended 1

By type:

Interventional 50

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 2
multicentric5to9 0
multicentricup10 45

Main Topics

Cohort/Consortium Investigators 4

Ongoing Clinical Trials

3 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Study of Sacituzumab Govitecan hziy and Pembrolizumab Versus Treatment of Physician s Choice and Pembrolizumab in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer
NCT05382286 — albumin-bound paclitaxel, triple negative breast neoplasms, breast neoplasms, paclitaxel, neoplasms, breast, therapeutics, carboplatin
Phase 3Active not recruiting2022
A Phase 3 Open Label Randomized Study of Dato DXd Versus Investigator s Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR Positive HER2 Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION Breast01)
NCT05104866 — mesylates, breast neoplasms, pharmaceutical preparations, neoplasms, tablets, drug therapy, hormones, neoplasm metastasis, vinorelbine, breast, capecitabine, chemotherapy
Phase 3Active not recruiting2021
A Study of T DXd in Participants With or Without Brain Metastasis Who Have Previously Treated Advanced or Metastatic HER2 Positive Breast Cancer
NCT04739761 — brain neoplasms, injections, epidermal growth factor, growth, breast neoplasms, brain, neoplasms, solutions, neoplasm metastasis, receptors, growth factor, breast, trastuzumab
Phase 3Active not recruiting2021

LeadR Networks

Main global connection map